Details

Autor(en) / Beteiligte

• Suma, Harumichi
• Yoshida, Yusuke
• Sugimoto, Tomohiro
• Matsuo, Yoshimi
• Law, Sze–Ming
• Nakashima, Ran
• Kobayashi, Hiroki
• Hosokawa, Yohei
• Ishitoku, Michinori
• Kohno, Hiroki
• Watanabe, Hirofumi
• Tokunaga, Tadahiro
• Mokuda, Sho
• Nojima, Takaki
• Hirata, Shintaro
• Sugiyama, Eiji

Titel

The clinical characteristics and predictors of severe digital ischemia in patients with anti‐aminoacyl transfer RNA synthetase antibodies

Ist Teil von

• Journal of dermatology, 2021-07, Vol.48 (7), p.1044-1051

Ort / Verlag

England: Wiley Subscription Services, Inc

Erscheinungsjahr

2021

Quelle

Wiley-Blackwell Full Collection

Beschreibungen/Notizen

• Severe digital ischemia (SDI), which presents with digital ulcers, necrosis, or gangrene, has been reported to be a rare manifestation of anti‐aminoacyl transfer RNA synthetase (ARS) antibody‐positive polymyositis/dermatomyositis or anti‐synthetase syndrome. A retrospective study was conducted between 2009 and 2020 at our department to investigate the clinical features of anti‐ARS antibody‐positive patients with SDI and identify their predictors. A total of 46 patients who were positive for anti‐ARS antibody were included, four of whom (8.7%) presented with SDI. The characteristics of the patients with SDI were as follows: the median age was 74 years, with 75% being female; anti‐Jo–1 antibody, Raynaud's phenomenon, interstitial lung disease, and myositis were observed in two (50%), four (100%), four (100%), and three patients (75%), respectively. Next, we reviewed the literature of anti‐ARS antibody‐positive patients with SDI and investigated the predictors of SDI by analyzing a total of 51 patients, including the previously reported five patients with SDI. Multivariable analyses revealed that Raynaud's phenomenon and myositis independently predicted the development of SDI in patients with anti‐ARS antibody. In conclusion, digital ulcers, necrosis, or gangrene seem to be more common presentations in our study, and Raynaud's phenomenon and myositis can predict the complications of SDI in anti‐ARS antibody‐positive patients.